litlas
Log inCreate account

Jos Jonkers

Active 1996–2025

161
Papers
37,566
Citations
98
h-index
152
i10-index

Citations

Citations per year for Jos Jonkers1980: 1 citations1981: 1 citations1996: 1 citations1997: 3 citations1998: 10 citations1999: 17 citations2000: 37 citations2001: 44 citations2002: 101 citations2003: 85 citations2004: 95 citations2005: 99 citations2006: 77 citations2007: 133 citations2008: 153 citations2009: 190 citations2010: 290 citations2011: 264 citations2012: 251 citations2013: 315 citations2014: 291 citations2015: 380 citations2016: 484 citations2017: 529 citations2018: 660 citations2019: 1,600 citations2020: 2,102 citations2021: 2,131 citations2022: 1,788 citations2023: 1,324 citations2024: 1,750 citations2025: 956 citations2026: 15 citations1982–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,323 citing papers, 25.5% of this breakdownChina: 2,558 citing papers, 12.3% of this breakdownUnited Kingdom: 1,714 citing papers, 8.2% of this breakdownGermany: 1,049 citing papers, 5% of this breakdownNetherlands: 1,033 citing papers, 5% of this breakdownItaly: 798 citing papers, 3.8% of this breakdownFrance: 737 citing papers, 3.5% of this breakdownCanada: 718 citing papers, 3.4% of this breakdownSpain: 595 citing papers, 2.9% of this breakdownJapan: 555 citing papers, 2.7% of this breakdownAustralia: 525 citing papers, 2.5% of this breakdownSwitzerland: 489 citing papers, 2.4% of this breakdown
0%25.5%Other 22.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology46.8%
  • Medicine39.4%
  • Immunology and Microbiology8%
  • Engineering2.2%
  • Neuroscience1.1%
  • Computer Science0.5%
  • Other2%

Topics

  • DNA Repair Mechanisms5.5%
  • PARP inhibition in cancer therapy4.8%
  • Cancer Cells and Metastasis4.2%
  • Cancer Genomics and Diagnostics3.7%
  • CRISPR and Genetic Engineering3%
  • Epigenetics and DNA Methylation2.2%
  • Other76.6%

Coauthors

All papers

Open in search
  1. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis

    Authors: Seth B. Coffelt, Kelly Kersten, Chris W. Doornebal, Jorieke Weiden, Kim Vrijland, Cheei‐Sing Hau, Niels J. M. Verstegen, Metamia Ciampricotti, Lukas J.A.C. Hawinkels, Jos Jonkers, Karin E. de Visser - Nature 2015 cited by 1,721

  2. Long‐term expanding human airway organoids for disease modeling

    Authors: Norman Sachs, Angelos Papaspyropoulos, Domenique D. Zomer-van Ommen, Inha Heo, Lena Böttinger, Dymph Klay, Fleur Weeber, Guizela Huelsz‐Prince, Nino Iakobachvili, Gimano D. Amatngalim, Joep de Ligt, Arne van Hoeck, Natalie Proost, Marco C. Viveen, Anna Lyubimova, Luc Teeven, Sepideh Derakhshan, Jeroen Korving, Harry Begthel, Johanna F. Dekkers, Kuldeep Kumawat, Emilio Ramos, Matthijs FM van Oosterhout, G. Johan A. Offerhaus, Dominique J. Wiener, Eduardo P. Olimpio, Krijn K. Dijkstra, Egbert F. Smit, Maarten van der Linden, Sridevi Jaksani, Marieke van de Ven, Jos Jonkers, Anne C. Rios, Emile E. Voest, Coline HM van Moorsel, Cornelis K. van der Ent, Edwin Cuppen, Alexander van Oudenaarden, Frank E. J. Coenjaerts, Linde Meyaard, Louis Bont, Peter J. Peters, Sander J. Tans, Jeroen S. van Zon, Sylvia F. Boj, Robert G. Vries, Jeffrey M. Beekman, Hans Clevers - The EMBO Journal 2019 cited by 1,080

  3. Landscape of somatic mutations in 560 breast cancer whole-genome sequences

    Authors: Serena Nik‐Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Głodzik, Xueqing Zou, Iñigo Martincorena, Ludmil B. Alexandrov, Sancha Martin, David C. Wedge, Peter Van Loo, Young Seok Ju, Marcel Smid, Arie B. Brinkman, Sandro Morganella, Miriam R. R. Aure, Ole Christian Lingjærde, Anita Langerød, Markus Ringnér, Sung‐Min Ahn, Sandrine Boyault, Jane E. Brock, Annegien Broeks, Adam P. Butler, Christine Desmedt, Luc Dirix, Serge Dronov, Aquila Fatima, John A. Foekens, Moritz Gerstung, Gerrit K. Hooijer, Se Jin Jang, David Jones, Hyung-Yong Kim, Tari King, Savitri Krishnamurthy, Hee Jin Lee, Jeong‐Yeon Lee, Yilong Li, Stuart McLaren, Andrew Menzies, Ville Mustonen, Sarah O’Meara, Iris Pauporté, Xavier Pivot, Colin A. Purdie, Keiran Raine, Kamna Ramakrishnan, F. Germán Rodríguez-González, Gilles Romieu, Anieta M. Sieuwerts, Peter T. Simpson, Rebecca Shepherd, Lucy Stebbings, Olafur A. Stefansson, Jon W. Teague, Stefania Tommasi, Isabelle Treilleux, Gert G. Van den Eynden, Peter Vermeulen, Anne Vincent‐Salomon, Lucy Yates, Carlos Caldas, Laura van’t Veer, Andrew Tutt, Stian Knappskog, Benita Kiat Tee Tan, Jos Jonkers, Åke Borg, Naoto T. Ueno, Christos Sotiriou, Alain Viari, P. Andrew Futreal, Peter J. Campbell, Paul N. Span, Steven Van Laere, Sunil R. Lakhani, Jorunn E. Eyfjord, Alastair M. Thompson, Ewan Birney, Hendrik G. Stunnenberg, Marc J. van de Vijver, John W.M. Martens, Anne‐Lise Børresen‐Dale, Andrea L. Richardson, Gu Kong, Gilles Thomas, Michael R. Stratton - Nature 2016 cited by 2,382

  4. Understanding and overcoming resistance to PARP inhibitors in cancer therapy

    Authors: Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, Jos Jonkers - Nature Reviews Clinical Oncology 2021 cited by 487

  5. PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

    Authors: Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, Anita K. Mehta, Aditi Kothari, Dan Wang, Tanvi H. Visal, Michelle K. Li, Jocelin Pinto, Jessica A. Castrillon, Emily Cheney, Peter Bouwman, Jos Jonkers, Sven Rottenberg, Jennifer L. Guerriero, Gerburg M. Wulf, Geoffrey I. Shapiro - Cancer Discovery 2019 cited by 720

  6. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

    Authors: Manuel Hidalgo, Frédéric Amant, Andrew V. Biankin, Eva Budínská, Annette T. Byrne, Carlos Caldas, Robert B. Clarke, Steven de Jong, Jos Jonkers, Gunhild M. Mælandsmo, Sergio Roman‐Roman, Joan Seoane, Livio Trusolino, Alberto Villanueva - Cancer Discovery 2014 cited by 1,760

  7. Replication fork stability confers chemoresistance in BRCA-deficient cells

    Authors: Arnab Ray Chaudhuri, Elsa Callén, Xia Ding, Ewa Gogola, Alexandra A. Duarte, Ji‐Eun Lee, Nancy Wong, Vanesa Lafarga, Jennifer A. Calvo, Nicholas J. Panzarino, Sam John, Amanda Day, Anna Vidal Crespo, Binghui Shen, Linda M. Starnes, Julian R. de Ruiter, J. Daniel, Panagiotis A. Konstantinopoulos, David Cortez, Sharon B. Cantor, Óscar Fernández-Capetillo, Kai Ge, Jos Jonkers, Sven Rottenberg, Shyam K. Sharan, André Nussenzweig - Nature 2016 cited by 949

  8. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis

    Authors: Max D. Wellenstein, Seth B. Coffelt, Danique E. M. Duits, Martine H. van Miltenburg, Maarten Slagter, Iris de Rink, Linda Henneman, Sjors M. Kas, Stefan Preković, Cheei‐Sing Hau, Kim Vrijland, Anne Paulien Drenth, Renske de Korte‐Grimmerink, Eva Schut, Ingrid van der Heijden, Wilbert Zwart, Lodewyk F.A. Wessels, Ton N. Schumacher, Jos Jonkers, Karin E. de Visser - Nature 2019 cited by 498

  9. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency

    Authors: Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C. Lee, Silviana Lee, Sumeet U. Nayak, John J. Krais, Pamela S. VanderVere-Carozza, Katherine S. Pawelczak, Jennifer A. Calvo, Nicholas J. Panzarino, John J. Turchi, Neil Johnson, Jos Jonkers, Eli Rothenberg, Sharon B. Cantor - Molecular Cell 2021 cited by 322

  10. The shieldin complex mediates 53BP1-dependent DNA repair

    Authors: Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, Marco Barazas, Stephen J. Pettitt, Alexanda K. Ling, Michele Olivieri, Alejandro Álvarez-Quilón, Nathalie Moatti, Michal Zimmermann, Stefano Annunziato, Dragomir B. Krastev, Feifei Song, Inger Brandsma, Jessica Frankum, Rachel Brough, Alana Sherker, Sébastien Landry, Rachel K. Szilard, Meagan Munro, Andrea McEwan, Théo Goullet de Rugy, Zhen‐Yuan Lin, Traver Hart, Jason Moffat, Anne‐Claude Gingras, Alberto Martín, Haico van Attikum, Jos Jonkers, Christopher J. Lord, Sven Rottenberg, Daniel Durocher - Nature 2018 cited by 675

  11. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

    Authors: Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates - Annals of Oncology 2020 cited by 481

  12. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Authors: Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez, Alba Llop‐Guevara, Yasir H. Ibrahim, Albert Gris‐Oliver, Sandra Bonache, Beatriz Morancho, Alejandra Bruna, Oscar M. Rueda, Zhongwu Lai, Urszula M. Polanska, Gemma N. Jones, Petra Kristel, L.D. Bustos, Marta Guzmán, Olga Rodríguez, Judit Grueso, Gemma Montalban, Ginevra Caratù, Francesco M. Mancuso, Roberta Fasani, José Jimenez, William Howat, Brian Dougherty, Ana Vivancos, Paolo Nucíforo, Xavier Serres, Isabel T. Rubio, Ana Oaknin, Elaine Cadogan, J. Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Joaquı́n Arribas, Jos Jonkers, Orland Dı́ez, Mark J. O’Connor, Judith Balmañà, Violeta Serra - Annals of Oncology 2018 cited by 427

  13. Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways

    Authors: Mirjam C. Boelens, Tony J. Wu, Barzin Y. Nabet, Bihui Xu, Yu Qiu, Taewon Yoon, Diana J. Azzam, Christina Twyman-Saint Victor, Brianne Z. Wiemann, Hemant Ishwaran, Petra J. ter Brugge, Jos Jonkers, Joyce M. Slingerland, Andy J. Minn - Cell 2014 cited by 804

  14. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

    Authors: Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, Wouter W. Wiegant, Jonas Schmid, Roebi de Bruijn, Dominic I. James, Sergi Guerrero Llobet, Daniël J. Vis, Stefano Annunziato, Bram van den Broek, Marco Barazas, Ariena Kersbergen, Marieke van de Ven, Madalena Tarsounas, Donald Ogilvie, Marcel A.T.M. van Vugt, Lodewyk F.A. Wessels, Jiřina Bártková, Irina Gromova, Miguel Andújar, Jiří Bártek, Massimo Lopes, Haico van Attikum, Piet Borst, Jos Jonkers, Sven Rottenberg - Cancer Cell 2018 cited by 385

  15. Induction of medulloblastomas inp53-null mutant mice by somatic inactivation ofRbin the external granular layer cells of the cerebellum

    Authors: Silvia Marino, Marc Vooijs, Hanneke van der Gulden, Jos Jonkers, Anton Berns - Genes & Development 2000 cited by 940

  16. Interrogating open issues in cancer precision medicine with patient-derived xenografts

    Authors: Annette T. Byrne, Denis Alférez, Frédéric Amant, Daniela Annibali, Joaquı́n Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budínská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles‐Marie, S. Gail Eckhardt, Eva González‐Suárez, Els Hermans, Manuel Hidalgo, Monika A. Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild M. Mælandsmo, Elisabetta Marangoni, Jean‐Christophe Marine, Enzo Médico, Jens Henrik Norum, Héctor G. Pálmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris‐Giménez, Sergio Roman‐Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino - Nature reviews. Cancer 2017 cited by 665

  17. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

    Authors: Peter Bouwman, Amal Aly, José Miguel Escandell, Mark Pieterse, Jiřina Bártková, Hanneke van der Gulden, Sanne Hiddingh, Maria Thanasoula, Atul Kulkarni, Qifeng Yang, Bruce G. Haffty, Johanna Tommiska, Carl Blomqvist, Ronny Drapkin, David J. Adams, Heli Nevanlinna, Jiří Bártek, Madalena Tarsounas, Shridar Ganesan, Jos Jonkers - Nature Structural & Molecular Biology 2010 cited by 1,021

  18. CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer

    Authors: Julia M. Houthuijzen, Roebi de Bruijn, Eline van der Burg, Anne Paulien Drenth, Ellen Wientjens, Tamara Filipovic, Esme Bullock, Chiara Svetlana Brambillasca, Emilia M. Pulver, Marja Nieuwland, Iris de Rink, Frank van Diepen, Sjoerd Klarenbeek, Ron Kerkhoven, Valerie G. Brunton, Colinda L. G. J. Scheele, Mirjam C. Boelens, Jos Jonkers - Nature Communications 2023 cited by 114

  19. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    Authors: Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir H. Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, María Vidal, Vicente Peg, Xavier Serres, Graham Dellaire, Jacques Simard, Paolo Nucíforo, Isabel T. Rubio, Rodrigo Dienstmann, J. Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J. O’Connor, Orland Dı́ez, Judith Balmañà, Violeta Serra - EMBO Molecular Medicine 2018 cited by 274

  20. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

    Authors: Jos Jonkers, Ralph Meuwissen, Hanneke van der Gulden, Hans Peterse, Martin van der Valk, Anton Berns - Nature Genetics 2001 cited by 1,067

  21. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance

    Authors: Peter Bouwman, Jos Jonkers - Nature reviews. Cancer 2012 cited by 617

  22. Genetically engineered mouse models in oncology research and cancer medicine

    Authors: Kelly Kersten, Karin E. de Visser, Martine H. van Miltenburg, Jos Jonkers - EMBO Molecular Medicine 2016 cited by 496

  23. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

    Authors: Dario Zimmerli, Chiara Svetlana Brambillasca, Francien Talens, Jinhyuk Bhin, Renske Linstra, Lou Romanens, Arkajyoti Bhattacharya, Stacey E. P. Joosten, Ana Moises Da Silva, Nuno Padrão, Max D. Wellenstein, Kelly Kersten, Mart de Boo, Maurits Roorda, Linda Henneman, Roebi de Bruijn, Stefano Annunziato, Eline van der Burg, Anne Paulien Drenth, Catrin Lutz, Theresa Endres, Marieke van de Ven, Martin Eilers, Lodewyk F.A. Wessels, Karin E. de Visser, Wilbert Zwart, Rudolf S.N. Fehrmann, Marcel A.T.M. van Vugt, Jos Jonkers - Nature Communications 2022 cited by 137

  24. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

    Authors: Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O.H. Nygren, Serge A.L. Zander, Patrick W.B. Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau, Robert Boulter, Aaron Cranston, Mark J. O’Connor, Niall M.B. Martin, Piet Borst, Jos Jonkers - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 949